Cancer treatments approved for use on NHS
Two new treatments for cancer have been approved for use by the NHS in Scotland.
The Scottish Medicines Consortium (SMC) has accepted Blinatumomab (also known as Blincyto) for treating adults with acute lymphoblastic leukaemia, a rare and aggressive form of leukaemia.
Rucaparib (also known as Rubraca) was accepted for use as a maintenance treatment for adults with advanced ovarian cancer, following first-line chemotherapy.
SMC chairman Dr Scott Muir said: “The committee is pleased to be able to accept these new medicines for use by NHS Scotland.
“Blinatumomab, used in the treatment of acute lymphoblastic leukaemia, reduces the risk of relapse and is expected to improve survival, giving patients extra time with their loved ones.
“Rucaparib will provide another treatment option for patients with advanced ovarian cancer.”
The Scottish Medicines Consortium has published its latest decisions (Julien Behal/PA)
The SMC advises on newly licensed medicines for use by NHS Scotland.
